Fujirebio Diagnostics Receives FDA Clearance for the HE4 EIA Assay for the monitoring of patients with ovarian cancer

The HE4 assay is CE marked in Europe and will be available to US-based physicians in July.

Malvern, PA, USA - June 19, 2008 - The HE4 assay is CE marked in Europe and will be available to US-based physicians in July.

> View the complete press release (PDF)